Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Moreover, the panelists emphasized that real-world evidence goes beyond clinical trial data. It involves continuous patient monitoring, proactive adverse effect management, and adapting protocols ...

A new study from Karolinska Institutet shows how a small antibody fragment can block fertilisation by targeting a key protein on the surface of the ...

Top-down proteomics: Intact proteins are ionized and analyzed directly, allowing for the study of proteoforms and ...

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

But Youle’s dismissal, along with 10 others at the NIH’s National Institute of Neurological Disorders and Stroke, underscores ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology.